High ORR with sequential regimen in CLL



Micrograph showing CLL
A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), results of the CLL2-BAG study suggest. Patients who received bendamustine followed by obinutuzumab and venetoclax achieved an ORR of 95%, and 87% of them were negative... [Read Article]

CHMP recommends midostaurin for FLT3+ AML, SM



Midostaurin (Rydapt)
Photo courtesy of Novartis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending approval for midostaurin (Rydapt®) as a treatment for acute myeloid leukemia (AML) and systemic mastocytosis (SM). If approved by the European Commission, midostaurin would be used in combination with standard daunorubicin and cytarabine... [Read Article]

CAR T-cell therapy ‘highly effective’ in high-risk CLL



Cameron Turtle, MBBS, PhD
Photo by Robert Hood,
Fred Hutchinson Cancer
Research Center
A chimeric antigen receptor (CAR) T-cell therapy is “highly effective” in high-risk patients with chronic lymphocytic leukemia (CLL), according to researchers. The CD19 CAR T-cell therapy, JCAR014, produced an overall response rate of 71% and a complete response (CR) rate... [Read Article]

Combo may be option for elderly patients with untreated AML



Andrew Wei, MBBS, PhD
The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. In a phase 1/2 study of such patients, VEN+LDAC was considered well-tolerated, conferring moderate myelosuppression and largely low-grade non-hematologic... [Read Article]

Blinatumomab granted full approval to treat rel/ref BCP-ALL



Vials of blinatumomab
powder and solution
Photo courtesy of Amgen
The US Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for blinatumomab (Blincyto®). The aim of the sBLA was to expand the indication for blinatumomab to include all patients with relapsed or refractory B-cell precursor acute lymphoblastic... [Read Article]

ODAC recommends approval of CTL019 in rel/ref ALL



CTL019 preparation
Photo from Penn Medicine
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval for the chimeric antigen receptor (CAR) T-cell therapy CTL019 (tisagenlecleucel). The committee voted 10 to 0 in favor of approving CTL019 for the treatment of pediatric and young adult patients... [Read Article]